The CGCI is continuously adding new clinical trials for the evaluation of promising immunotherapy treatments. Trials are categorized in phases:
Phase 1: The earliest of human clinical trials, Phase I studies focus on ensuring the safety of any new drug, including evaluating any side effects and dosage levels.
Phase 2: Further evaluation of the safety of the medication and how well it works.
Phase 3: Compares the new treatment with the standard treatment currently available.
Phase 4: Usually done after FDA approval, it refines optimal dosages, types of patients who may benefit, and long-term effects of the treatment.
For more information about open clinical trials please call:
314-273-2355/ 833-273-CELL (2355)